These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 23420110

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Daclizumab use in patients with pediatric multiple sclerosis.
    Gorman MP, Tillema JM, Ciliax AM, Guttmann CR, Chitnis T.
    Arch Neurol; 2012 Jan 02; 69(1):78-81. PubMed ID: 22232346
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM, García-Sánchez MI, Costa-Frossard L, Espiño M, Roldán E, Páramo D, Lucas M, Izquierdo G, Álvarez-Cermeño JC.
    Arch Neurol; 2012 Feb 02; 69(2):191-7. PubMed ID: 22332187
    [Abstract] [Full Text] [Related]

  • 9. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM, Johnson BH, Wenten M, Watson C.
    Clin Ther; 2013 Oct 02; 35(10):1501-12. PubMed ID: 24139422
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study Group.
    Arch Neurol; 2012 Feb 02; 69(2):239-45. PubMed ID: 22332191
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
    Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B.
    Eur Neurol; 2010 Feb 02; 63(2):101-6. PubMed ID: 20090344
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, Stüve O, Salvetti M, Centonze D.
    Eur J Neurol; 2013 Jan 02; 20(1):87-94. PubMed ID: 22741530
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.